Read by QxMD icon Read

Leukemia Research

Abhishek A Mangaonkar, Naseema Gangat, Aref Al-Kali, Michelle A Elliott, Kebede H Begna, Curtis A Hanson, Rhett P Ketterling, Alexandra P Wolanskyj-Spinner, William J Hogan, Mark R Litzow, Mrinal M Patnaik
INTRODUCTION: The 2016 World Health Organization (WHO) classification of myeloid neoplasms reclassified patients with myelodysplastic syndromes (MDS) with multilineage dysplasia (MLD) based on the presence or absence of ring sideroblasts (RS). We performed this study to validate this change in the context of relevant gene mutations. METHODS: WHO-defined MDS and MLD were identified with detailed clinical, cytogenetic and outcomes data. A 32-gene targeted exome sequencing panel was performed on bone marrow samples obtained at diagnosis...
July 11, 2018: Leukemia Research
Kausar J Jabbar, C Cameron Yin, Carlos E Bueso-Ramos, Rajyalakshmi Luthra, L Jeffrey Medeiros, Zhuang Zuo
No abstract text is available yet for this article.
July 10, 2018: Leukemia Research
Martin März, Svenja Meyer, Ulrike Erb, Christina Georgikou, Martin A Horstmann, Svetlana Hetjens, Christel Weiß, Petra Fallier-Becker, Elodie Vandenhaute, Hiroshi Ishikawa, Horst Schroten, Matthias Dürken, Michael Karremann
Despite the high prevalence of central nervous system (CNS) involvement in relapsing pediatric acute lymphoblastic leukemia (ALL), our understanding of CNS invasion is still vague. As lymphoblasts have to overcome the physiological blood-CNS barriers to enter the CNS, we investigated the cellular interactions of lymphoblasts with the choroid plexus (CP) epithelium of the blood-cerebrospinal fluid barrier (BCSFB). Both a precurser B cell ALL (pB-ALL) cell line (SD-1) and a T cell ALL (T-ALL) cell line (P12-Ishikawa) were able to actively cross the CP epithelium in a human in vitro model...
July 8, 2018: Leukemia Research
Sotirios G Papageorgiou, Ioannis Kotsianidis, Christos K Kontos, Argyris Symeonidis, Athanasios Galanopoulos, Eleftheria Hatzimichael, Elias Poulakidas, Panagiotis Diamantopoulos, Theodoros P Vassilakopoulos, Panagiotis Zikos, Helen Papadaki, Eleni Bouronikou, Panayiotis Panayiotidis, Nora-Athina Viniou, Vasiliki Pappa
No abstract text is available yet for this article.
July 7, 2018: Leukemia Research
William J Archibald, Philip J Meacham, AnnaLynn M Williams, Andrea M Baran, Adrienne I Victor, Paul M Barr, Deepak M Sahasrahbudhe, Clive S Zent
Melanoma is significantly more common and is associated with a poorer prognosis in patients with an underlying B-cell malignancy. This study reports on the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) and a subsequent diagnosis of melanoma. In the Wilmot Cancer Institute CLL cohort, which includes 470 patients followed for 2849 person-years, 18 patients (3.8%) developed 22 melanomas. Fourteen melanomas were invasive, a significantly higher rate as compared with the age and sex matched general population (standardized incidence ratio [SIR] 6...
July 6, 2018: Leukemia Research
Kasper Warrick, Sandra K Althouse, April Rahrig, Joy Rupenthal, Sandeep Batra
BACKGROUND: High Risk (HR) or Very High Risk (VHR) acute lymphoblastic leukemia (ALL) treated with 4 drug induction chemotherapy is often associated with adverse events. The aim of this study was to identify risk factors associated with a prolonged inpatient length of stay LOS during induction chemotherapy. PROCEDURE: Data from patients (N = 73) (age<21 years) was collected through a retrospective chart review. Univariable and multivariable logistic regression was used to test for statistical significance...
June 30, 2018: Leukemia Research
John M Bennett
No abstract text is available yet for this article.
June 21, 2018: Leukemia Research
Antonio Almeida
No abstract text is available yet for this article.
June 19, 2018: Leukemia Research
Jill A Bell, Aaron Galaznik, Eileen Farrelly, Marlo Blazer, Sharanya Murty, Augustina Ogbonnaya, Michael Eaddy, Robert J Fram, Douglas V Faller, Vamsi Kota
This retrospective claims database study examined healthcare utilization (HCU) and costs associated with acute myeloid leukemia (AML) in 237 elderly patients who received chemotherapy or a stem cell transplant (SCT) following AML diagnosis. Patients with secondary AML were excluded. Over the entire follow-up period, 92.0% of patients had ≥1 inpatient admission; 85.7% had ≥1 AML-related admission, and 42.6% had ≥1 non-AML-related admission. During inpatient admissions, 39.2% of patients had ≥1 intensive care unit (ICU) admission, with 20...
June 18, 2018: Leukemia Research
Jorge Gabriel Rossi, Patricia Rubio, Cristina N Alonso, Andrea R Bernasconi, Elisa O Sajaroff, Jorge Digiorge, Edgardo Baialardo, Silvia Eandi-Eberle, Myriam Guitter, Angelica Fernandez-Barbieri, Raquel Mitchell, Maria Sara Felicea
Several conventions have been established in order to define and characterize Mixed Phenotype Acute Leukemia (MPAL). However, megakaryocytic markers have not been included in the definition of MPAL neither in the European Group for the Immunological Characterization of Leukemias (EGIL) proposal nor in any of the WHO Classification of Tumors issues. We report four pediatric acute leukemia (AL) cases (prevalence: 0.18%) with megakaryoblasts co-expressing the T-specific antigen CD3 (cytoplasmic), together with a very homogeneous antigen profile of immature cells and other lymphoid traits...
June 18, 2018: Leukemia Research
Merav Barzilai, Aaron Polliack, Irit Avivi, Yair Herishanu, Ron Ram, Catherine Tang, Chava Perry, Nadav Sarid
Patients with inflammatory bowel disease (IBD) on immunosuppression are at risk of developing lymphoma, particularly primary gastrointestinal (GI) tract non-Hodgkin lymphoma. Primary GI Hodgkin lymphoma (HL) in this setting, however, is rare and poorly defined. Here we review the available literature and also report a patient with Crohn's disease (CD) who developed GI HL. Our search yielded 12 single case studies and 7 case series involving 22 patients published between 1978-2016. Twenty-one (91%) patients had CD, and 2 had ulcerative colitis...
June 16, 2018: Leukemia Research
Tingting Pan, Jiaqian Qi, Tao You, Liping Yang, Depei Wu, Yue Han, Li Zhu
AIM: To compare the efficacy and safety between hypomethylating agent (HMA) alone and the combination of HMA and histone deacetylase inhibitor (HDACi) in myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). METHODS: We performed a systematic review and meta-analysis of all available cohort studies regarding the comparison of HMA alone and in combination with HDACi for MDS and AML. Embase and Pubmed databases were searched for relevant studies. The overall hazard ratios for the HMA alone and HDACi combination were extracted...
June 9, 2018: Leukemia Research
M Gavillet, O Spertini, S Blum
No abstract text is available yet for this article.
June 8, 2018: Leukemia Research
Ashley Leak Bryant, Sarah W Drier, Sejin Lee, Antonia V Bennett
The purpose of this systematic literature review was to identify clinical trials of MDS and AML that included patient-reported outcome (PRO) instruments, and to summarize the symptom and other health related quality of life (HRQOL) concepts most frequently assessed and the PRO instruments that were used. Sixteen manuscripts describing 14 distinct trials met all criteria (i.e., phase 2 or 3 clinical trial for MDS or AML which included PRO assessment) and were published between 1996-2017. In trials evaluating anemia, PRO scores showed significant improvement in relevant domains (e...
June 7, 2018: Leukemia Research
Akira Matsuda, Hiroshi Kawabata, Kaoru Tohyama, Tomoya Maeda, Kayano Araseki, Tomoko Hata, Takahiro Suzuki, Hidekazu Kayano, Kei Shimbo, Kensuke Usuki, Shigeru Chiba, Takayuki Ishikawa, Nobuyoshi Arima, Masaharu Nohgawa, Akiko Ohta, Yasushi Miyazaki, Sinnji Nakao, Keiya Ozawa, Shunya Arai, Mineo Kurokawa, Kinuko Mitani, Akifumi Takaori-Kondo
The diagnosis of myelodysplastic syndromes (MDS) is based on morphology and cytogenetics. However, limited information is currently available on the interobserver concordance of the assessment of dysplastic lineages (<10% or ≥10% in bone marrow (BM)). The revised International Prognostic Scoring System (IPSS-R) described a new threshold (2%) for BM blasts. However, the interobserver concordance of the categories (0-≤2% and >2-<5%) has limited data. The purpose of the present study was to investigate the assessment of dysplastic lineages and IPSS-R reproducibility...
June 7, 2018: Leukemia Research
Sung-Eun Lee, Soo-Young Choi, Soo-Hyun Kim, Saengsuree Jootar, Hyeoung-Joon Kim, Sang-Kyun Sohn, Joon Seong Park, Sung-Hyun Kim, Dae-Young Zang, Suk-Joong Oh, Dong-Wook Kim
The aim of this study was to investigate the efficacy of nilotinib (NIL) versus high-dose imatinib (IM) versus sustained standard-dose IM for patients with chronic myeloid leukemia (CML) with suboptimal molecular response to first-line IM therapy. Patients with CML who achieved complete cytogenetic response (CCyR) but not major molecular response (MMR) after 18-24 months on first-line IM therapy were enrolled and divided into three treatment cohorts: NIL 800 mg/day (Cohort 1, n = 28) and IM 800 mg/day (Cohort 2, n = 28) in the RE-NICE study, and sustained IM 400 mg/day (Cohort 3, n = 52) in clinical practice...
June 7, 2018: Leukemia Research
Subhadip Das, Rebecca Dielschneider, Aaron Chanas-LaRue, James B Johnston, Spencer B Gibson
Lysosomes are the most acidic vesicles within mammalian cells and are promising targets for the treatment of breast cancer, glioblastomas and acute myeloid leukemia (AML). Our previous studies have shown that chronic lymphocytic leukemia (CLL) cells are also sensitive to lysosome disruption and cell death, by siramesine or chemotherapy. In the present study, we screened the antimalarial drugs, mefloquine, atovaquone, primaquine, and tafenoquine, for their effects on lysosome disruption and cytotoxicity in primary CLL cells...
June 7, 2018: Leukemia Research
Nicholas L Jackson Chornenki, Chatree Chai-Adisaksopha, Darryl P Leong, Deborah M Siegal, Christopher M Hillis
Therapy in Polycythemia Vera (PV), a myeloproliferative neoplasm, focuses on reducing cardiovascular (CV) risk without increasing bleeding or hematological progression. However, the real-world practice of treating PV in North America is understudied. We performed a retrospective cohort study of newly diagnosed PV (JAK2V617F mutation positive) patients in Hamilton, Canada to fill this knowledge gap. Out of 108 patients included, (n = 45, 41.7%) patients did not receive therapy consistent with contemporary treatment guidelines...
June 4, 2018: Leukemia Research
Hanna Janiszewska, Aneta Bąk, Katarzyna Skonieczka, Anna Jaśkowiec, Marek Kiełbiński, Anna Jachalska, Maria Czyżewska, Bożena Jaźwiec, Małgorzata Kuliszkiewicz-Janus, Jarosław Czyż, Kazimierz Kuliczkowski, Olga Haus
CHEK2 plays a key role in cellular response to DNA damage, and also in regulation of mitosis and maintenance of chromosomal stability. In patients newly diagnosed with myelodysplastic syndrome (MDS, n = 107) or acute myeloid leukemia (AML, n = 117) congenital CHEK2 mutations (c.444 + 1G > A, c.1100delC, del5395, p.I157 T) were tested by PCR and sequencing analysis. The karyotype of bone marrow cells of each patient was assessed at disease diagnosis using classical cytogenetic methods and fluorescence in situ hybridization...
June 3, 2018: Leukemia Research
Vera Vulaj, Anthony J Perissinotti, James R Uebel, Victoria R Nachar, Gianni B Scappaticci, Ashley Crouch, Dale L Bixby, Patrick W Burke, Ivan Maillard, Moshe Talpaz, Bernard L Marini
Patients with secondary acute myeloid leukemia (sAML) have poor outcomes, with CR/CRi rates of 25-35% with standard 7 + 3 induction chemotherapy, while single center non-comparative analyses suggest promising outcomes with FLAG. We conducted a single-center, retrospective cohort study assessing outcomes in treatment-naïve patients with sAML treated with fludarabine, high-dose cytarabine, and granulocyte colony-stimulating factor (FLAG, n = 40) compared with 7 + 3 (n = 66). Median patient age was 63 years (range: 27-82) in the FLAG group and 60 years (range: 21-76) in the 7 + 3 group (P = 0...
June 1, 2018: Leukemia Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"